Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences

AUSTIN, Texas, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. AGLE, a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced that Anthony G. Quinn, M.B. Ch.B, Ph.D., president and chief executive officer of Aeglea, will participate in the following investor conferences in December.

Evercore ISI 2^nd Annual HealthCONx Conference
Date: Tuesday, December 3, 2019
Presentation Time: 8:45 a.m. ET
Location: Boston, MA

Piper Jaffray 31st Annual Healthcare Conference
Date: Wednesday, December 4, 2019
Presentation Time: 4:30 p.m. ET
Location: New York, NY

Live-streaming webcasts of these presentations will be available on the Presentations & Events section of the Aeglea BioTherapeutics investor relations website.

About Aeglea BioTherapeutics
Aeglea is a clinical-stage biotechnology company that engineers next generation human enzymes with enhanced properties and novel activity to provide solutions for diseases with unmet medical need. Aeglea is developing pegzilarginase, its lead product candidate, for the treatment of Arginase 1 Deficiency which has received both Rare Pediatric Disease and Breakthrough Therapy Designation. Aeglea has two programs in IND-enabling studies for Homocystinuria and Cystinuria and an active discovery pipeline. For more information, please visit http://aegleabio.com.

Media Contact:
David Calusdian
Sharon Merrill Associates
617.542.5300
AGLE@investorrelations.com

Investor Contact:
Joey Perrone
Senior Director, Finance & Investor Relations
Aeglea BioTherapeutics
investors@aegleabio.com